The British drug manufacturer based in Cambridge announced that his investment will finance a new Department of Drug Production in Virginia and expand the research and development activities and production of cellular therapy in several states.
See also: Trump's duties hit General Motors. That's what their losses are
As “The Guardian” notes, The company's announcement appears when Donald Trump threatens to impose duties of up to 200 percent. for pharmaceutical products produced outside the United States. The president said last month that pharmaceutical companies may be from 12 to 18 months to transfer production to the USA.
Howard Lutnick, Secretary of US trade, said that Trump's customs focused on the end of relying on foreign supplies of key pharmaceutical products.
“We are proud that Astrazeneca decided to transfer significant pharmaceutical production to our coast. This historical The investment will bring tens of thousands of jobs in the USA and ensure that medicines sold in our country will be produced here” – said Lutnick, whose words” The Guardian “quotes.
Astrazeneca will invest $ 50 billion. in the USA until 2030, he wants to overtake Trump's customs
The general director of Astrazeneca, Pascal Soriot, said that investment worth $ 50 billion It will support the company's ambition to reach $ 80 billion. revenues by 2030. The company expects that then 50 percent sales will come from the USA.
In 2024, the company generated revenues of $ 54.1 billion. The multi -billion involvement of Astrazeneca in the United States “Times” combines with the alleged Soriot plan to transfer the stock market quotations of London to New York.
See also: For now, Trump's customs do not harm Europe. The trade surplus from the USA is growing
Astrazeneca joins the long list of companies revealing investments in the USA in the face of potential Trump administration duties. As “The Guardian” reminds, already in April the Swiss drug producer Roche announced in April that in the next five years he will invest $ 50 billion. in production in the USA, which according to the group will create over 12,000 jobs.
His rival Novartis announced that he would spend $ 23 billion in the USA, and the American pharmaceutical company Johnson & Johnson announced in March that he would invest $ 55 billion. in production, research and development.
